CAS 951326-02-6

Ulimorelin Hydrochloride Hydrate

Produit contrôlé

CAS : 951326-02-6

Applications Ulimorelin Hydrochloride Hydrate is a macrocyclic ghrelin receptor agonists for treatment of gastrointestinal disorders involving low motility.
References Shaw, M. et al.: Dis. Colon Rectum., 56, 888 (2013);

Formule : C₃₀H₃₉FN₄O₄·ClH·H₂O

Couleur et forme : Neat

Masse moléculaire : 593.13

Ref: TR-U700815

Ulimorelin hydrochloride hydrate

CAS : 951326-02-6

Ulimorelin hydrochloride hydrate is an inhibitor that has been shown to selectively induce apoptosis in cancer cells. This medicinal compound is a protein analog that inhibits the activity of kinases, which are enzymes that play a critical role in tumor growth and progression. Ulimorelin hydrochloride hydrate has been tested on human cancer cell lines and has demonstrated potent anticancer activity. Additionally, it has been found to have inhibitory effects on Chinese hamster ovary (CHO) cells, which suggests potential therapeutic applications beyond cancer treatment. Ulimorelin hydrochloride hydrate is excreted primarily via urine and may be the basis for future research in developing new kinase inhibitors for treating various types of cancer.

Formule : C₃₀H₄₂ClFN₄O₅

Degré de pureté : Min. 95%

Masse moléculaire : 593.1 g/mol

Ref: 3D-BNB32602